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INTRODUCTION
Resumative synthesis of contents:
It is time for further renoprotection
Over the past decade, as industrialized nations strug-
gled to cope with the fiscal stress imposed by a continu-
ously expanding population of individuals with end-stage
renal failure (ESRD), excitement over the concept of
preventing or delaying uremia gained momentum. In the
United States, for example, an estimated 20 to 25 million
people currently have varying degrees of renal impair-
ment that will, if not interrupted, deteriorate to ESRD
within months to years. That ESRD may not be inevita-
ble has been learned from success in slowing renal func-
tional decline in both type 1 and type 2 diabetes by
careful metabolic control using diet, oral hypoglycemic
agents, and insulin. Multiple reports have indicated that
pharmacologic interference with angiotensin-converting
enzyme by either direct enzyme inhibition or receptor
blockade retard progression of nephropathy. The con-
cept of renoprotection has gained acceptance as the em-
blem for renal investigators sharing interest in inter-
dicting the mounting toll extracted by kidney loss.
Presently, several promising paths to stop the march
toward ESRD are under intense inquiry, with special
focus on the roles of anemia, bone disease, nutrition,
and perturbed molecular biology. As the latest in a series
of symposiums convened at the Avram Conference Cen-
ter, Long Island College Hospital in Brooklyn, New
York City, “Management of Comorbidities in Kidney
Disease” was actually directed toward turning off the
renal damage and improving the quality of life once
on dialysis. This was accomplished by state-of-the-art
lectures, workshops, and panels with lively debates. Each
participant was asked to bring a manuscript for peer
review, so that this huge body of new information could
be made available worldwide. Indeed, it is neither possi-
ble nor desirable to disconnect the consequence of kid-
ney malfunction, per se, from its wide-reaching impact
on other vital organ systems.
Launching the vital theme that anemia is more than
a comorbid annoyance to those with renal insufficiency,
Avram et al recount their unique 15-year single-center
observational study of hemoglobin as a correlate of both
prealbumin and survival in 529 hemodialysis and 326
peritoneal dialysis patients. For hemodialysis or perito-
neal dialysis patients with a hemoglobin of 12 g/dL or
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higher at study enrollment, survival throughout their
course of dialytic therapy, as well as after 15 years, was
significantly (P   0.05) greater. The correlation dis-
cerned by Avram et al was greater for nondiabetic than
diabetic patients, probably due to anemia induced by
the adverse influence of multiple comorbidities in the
diabetic cohort. Avram et al conclude that anemia is a
modifiable risk factor, and this needs to be applied to
current practice parameters. Reinforcing this view is the
paper by Madhumathi Rao and Brian J.G. Pereira.
Moreover, highlighting major recently launched multi-
center, randomized, prospective trials designed to deter-
mine whether correction of anemia will reduce morbidity
and mortality of patients with chronic kidney disease
(CKD), they provide what amounts to a detailed prelude
to the conference as a whole. Noting the “growing aware-
ness” that raising hemoglobin levels in anemic CKD
patients decreases the incidence of cardiovascular events,
Rao and Pereira list what they term “issues needing
resolution.” Key among the unresolved “many questions
regarding optimal anemia management” are the relative
and absolute benefits of partial versus full correction of
anemia. It must be established by empirical trial, the
authors comment, precisely which target hemoglobin
concentration (hematocrit) to select as a treatment ob-
jective.
Using the glomerular filtration rate (GFR) estimation
equation from the Modification of Diet in Renal Disease
(MDRD) study, Rao and Pereira underscore a preva-
lence of CKD, defined as a GFR 60 mL/min/1.73 m2,
as approximately 8.3 million individuals, or 4.7% of the
United States population. Also included in the MDRD
study was the alarming inference that 85% of patients
with impaired kidney function (GFR below 55 mL/min/
1.73 m2) will continue to lose remaining kidney function
at a rate of 4 mL/minute per year. Based on this progres-
sive quality of CKD, and the improving survival of
ESRD, kidney failure now has enormous impact on
health care systems and national economic stability. Not
only does CKD induce a decreased quality of life, but
by its progression to ESRD results in a nearly eight-fold
reduction in life span. A simple measure of the financial
burden imposed by ESRD patients (who comprise 1.1%
of Medicare beneficiaries but consume 5% of expendi-
tures) is their total cost in the United States of $17.9
billion in 1999, representing a 7.2% increase over the
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previous year. Rao and Pereira sound a clear alarm for
medicine to “Do Something!,” echoing the United States
Renal Data System (USRDS) projection that by the year
2010, the United States will have to provide care for
661,330 ESRD patients, at an estimated Medicare ESRD
cost of over $28 billion.
To known strategies that may lessen the progression
of CKD including normalization of hypertensive blood
pressures, establishing euglycemia in diabetic patients,
and modulating dietary protein consumption, treatment
with erythropoietin (EPO) may well become a central
component of an increasingly complex regimen. As sug-
gested by the authors, the benefits of improving anemia,
although expensive and labor-intensive, may gain the
dual rewards of enhanced life quality plus increased lon-
gevity. Overall, it is the testing of this hypothesis that
stands at the center of any regimen for comprehensive
management of CKD.
Furthermore, Avram et al call attention to the trend
associating hemoglobin and prealbumin in their hemodi-
alysis and peritoneal dialysis patients, which should gain
statistical significance as cohort size increases.
Derived from the Avram et al report, it follows that
minimizing anemia before the start of renal replace-
ment therapy maximizes the chance for survival. In his
report, Toto continues this line of thought—that “anemia
is a modifiable risk factor” in chronic kidney disease
(CKD)—by first summarizing evidence indicting anemia
to be a “powerful risk factor for cardiovascular disease.”
He notes that it is cardiovascular disease that leads the
causes of death in CKD with a mortality rate 30 to 50
times greater in hemodialysis patients than in age-
matched normal individuals. Toto further states that ane-
mia is a risk factor common to both renal and cardiovas-
cular disease, but that it has not been carefully studied.
Future studies of anemia in CKD should include evalua-
tion of the effect of correcting anemia on both cardiovas-
cular and renal outcomes.
Updating the United States Renal Data System’s An-
nual Report, Collins et al reported that diabetes, now
fully recognized as the leading cause of ESRD, “is in-
creasing in the general Medicare population at a rate of
4.4% per year.” Echoing the alert sounded by Toto,
Collins et al noted that hospitalization for heart failure
is five times more frequent in predialysis patients than
in non-CKD patients. The USRDS continues to serve
as the most reliable and extensive resource for all in-
volved in management of kidney failure. With an ever-
expanding data set, it is certain that mining the USRDS
will prove fruitful in ultimately defining correlations with
specific hemoglobin (hematocrit) levels in each age, diag-
nosis, and racial subset that is tallied nationwide.
Focusing specifically on the “potential adverse effects
of chronic anemia on the myocardium,” Pereira and Sar-
nak conclude that anemia is an independent risk factor
for left ventricular hypertrophy and predict cardiovascu-
lar disease adverse outcomes in patients with CKD and
heart failure. These investigators caution that, “although
studies may demonstrate an association between anemia
and cardiovascular disease outcomes,” the two may not
be direct cause and effect. After exploring confounding
factors such as anemia resulting from hemodilution asso-
ciated with heart failure, Pereira and Sarnak recount
evidence that anemia and systolic blood pressure were
the clearest links to left ventricular hypertrophy. Citing
a retrospective analysis of 78,974 Medicare beneficiaries
65 years or older hospitalized with acute myocardial in-
farction, the authors note that mortality was higher with
lower hematocrits. These authors also underscore the
need for further clinical studies and trials of the value
of correcting anemia in CKD patients.
Suggesting the utility of defining a Cardio Renal Ane-
mia (CRA) Syndrome, Silverberg et al include conges-
tive heart failure (CHF), chronic renal insufficiency, and
anemia as its components. The lynch pin of CRA is CHF,
which is found in “up to 64% of patients with CKD
referred to nephrologists.” Silverberg et al make the
important point that unless the anemia, constant in CRA,
is corrected, the CHF will often not improve. The authors
propose routine echocardiograms and “possibly measur-
ing B-type natriuriteic peptide,” as well as exercising
a responsibility to “recognize, investigate, or treat the
anemia” that is present in CKD. There is no question
that aggressive cardiac monitoring pays off in terms of
ESRD patient survival. Our colleagues performing kid-
ney transplants were the first to point out more than a
decade ago that unless coronary artery disease is de-
tected and treated in intended diabetic kidney transplant
recipients, the post-transplant mortality would be unac-
ceptably high.
Characterizing anemia “as a prognostic factor” in all
stages of heart failure, Mancini and Kunavarapu com-
plete the examination of the strong contributing role of
the incidence and prevalence of anemia in the genesis
of morbidity and mortality in CKD. Employing a long-
acting erythropoietin, darbopoietin alfa in 300 anemic
patients with heart failure, the authors are supervising
a double-blind, randomized, placebo-controlled, multi-
center trial that may well produce needed answers, as
end points of exercise tolerance and survival are weighed
in both groups. From a subjective perspective, I have no
doubt that correction of anemia in patients with chronic
renal disease on or off dialysis results in better rehabilita-
tion and strongly enhances life quality.
Mushnick et al examine the importance of bioimpe-
dance parameters as indicators of nutritional status and
survival in peritoneal dialysis patients. Introducing the
new-to-nephrology technique of bioelectrical impedance
analysis (BIA), in a subgroup of 48 peritoneal dialysis
patients, the investigators suggest that this simple, inex-
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pensive physical measurement might yield as much in-
formation as that gained from laborious and expensive
blood chemistry testing. BIA parameters, phase angle,
and reactance were strongly correlated with prealbumin
and other serum nutritional markers. They also reported
that phase angle was an independent predictor of more
than two years’ survival in peritoneal dialysis patients.
Addressing retinopathy, which is the major debilitat-
ing comorbidity accompanying diabetic nephropathy,
Friedman and L’Esperance, Jr. presented a small yet intri-
guing series of azotemic diabetic patients whose macular
edema remarkably improved upon raising their red cell
mass by treatment with erythropoietin. Proposing that
their experience in three patients might extrapolate to
all diabetic patients with eye disease, the authors provide
further reason to be intolerant of anemia in CKD. As
is true for the need for frequent periodic collaboration
between cardiologist and nephrologists, ophthalmologic
guidance should be a routine practice in the management
of every diabetic ESRD patient. Early laser photocoagu-
lation coupled with blood pressure normalization and
careful metabolic control will nearly always preempt
blindness in diabetic ESRD patients.
Erythrocyte synthesis is contingent on marrow stimu-
lation by erythropoietin plus adequate stores of iron.
Exploring this relationship, Nissenson and Charytan
note that the first results of supplementation with oral
iron were “disappointing” in hemodialysis patients. They
then present recent results of the effect of administering
“a new generation of oral iron product” termed heme-
iron polypeptide (HIP). HIP, produced by hydrolysis of
bovine hemoglobin, employs the heme porphyrin ring
to deliver iron to key intestinal absorption sites with a
bioavailability “up to 10 times higher than non-heme
iron.” In a six-month trial of HIP (without parenteral
iron), stable hemoglobin values were maintained. Until
further larger trials of HIP are completed, treatment in
hemodialysis facilities will be based on parenteral iron
preparations. They believe that the currently available
iron formulations, “both iron sucrose and iron gluconate,
are safer than iron dextran,” which should be used only
in “extraordinary circumstances.”
Relying on “an accelerated regimen of high dose intra-
venous iron sucrose therapy,” Blaustein et al conducted a
prospective study of CKD patients whose serum ferritin
values were 500 ng/mL, while transferring saturation
was 40%. They administered 500 mg of intravenous
iron sucrose over three hours on two consecutive days
to a study population consisting of 52 inpatients and
56 outpatients with CKD. Although iron sucrose for
parenteral use has been available for more than 50 years,
the present study affirmed both the drug’s efficacy and
low toxicity. Blaustein et al believe that the rapid dosing
method utilized may hold an economic advantage, espe-
cially in terms of reduced expenditure for personnel.
While no universal answer as to what to do in manage-
ment of iron deficiency in CKD patients is on hand,
this rapid, inexpensive manner of coping with a difficult
problem holds substantial promise.
Greenwood and Levin et al wrote about erythropoie-
tin dose variation in different facilities in different coun-
tries and its relationship to drug resistance. Some United
States facilities use nearly twice the EPO dose as is used
in the United Kingdom. Factors related to inflammation,
low albumin, the use of tunneled catheters, and low pro-
tein catabolic rate (nPCR) correlated with low hemoglo-
bin and relative EPO resistance.
Addressing the issue first raised in the literature by
Avram’s laboratory, Fein et al explore the role of preal-
bumin and inflammation as correlates of mortality in 63
peritoneal dialysis patients in whom C-reactive protein
(CRP) and other nutritional markers were serially mea-
sured. Fein et al found that CRP was inversely correlated
with BIA, prealbumin, and other nutritional markers at
enrollment for ESRD therapy.
Responding to the question of why serum albumin
concentration may prove resistant to therapy in dialysis
patients, Kaysen begins by noting that reduced protein
and calorie intake does not cause hypoalbuminemia in
otherwise healthy individuals. The genesis of reduced
serum albumin levels in dialysis patients is the product
of inflammation plus reduced protein intake, which
blunts the defense of decreased albumin fractional cata-
bolic rate and resting energy expenditure that are normal
compensatory mechanisms. Inflammation in dialysis pa-
tients is caused by infections at the vascular access site
and other more occult infections. Hypoalbuminemia is
also strongly associated with chronic comorbid condi-
tions such as chronic obstructive pulmonary disease, which
may not be readily reversible even if clearly identified.
Seeking an answer to why ESRD has a higher inci-
dence in blacks than in whites, August and Suthanthiran
explore the possible role of transforming growth factor-
(TFG-) as a contributory factor to the renal fibrosis of
progressive renal insufficiency. Testing the hypothesis
that TFG- may be more frequently expressed in blacks
than in whites, blood levels were compared in cohorts
of ESRD patients, those with hypertension, and normal
patients. In all three subsets, TFG- levels were higher
in blacks. Preliminary genetic analysis supports the infer-
ence that TFG- DNA polymorphisms may distinguish
hypertensive from normal patients. Increasingly, nephrol-
ogists wishing answers to seminal dilemmas must turn
to their colleagues conducting studies at the molecular
biology level. It is probable that derivative studies may
find that TFG- and its molecular cousins may well lie
at the root of why kidney disorders progress.
Returning to the central importance of cytokines in
the pathogenesis of CKD, Klahr and Morrissey present
their findings in blocking fibrosis in a rat model in which
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ureteral ligation stimulates tubulointerstitial nephritis by
stimulating both TFG- and tumor necrosis factor-
(TNF-). By utilizing both knockout mice and an orally
active angiotensin-converting enzyme inhibitor, the in-
vestigators conclude that TNF- is a factor in the genesis
of myeloblast proliferation and nuclear factor kappa B
(NK-B) activation in the kidney during ureteral obstruc-
tion. In a complex series of studies, Klahr and Morrissey
further demonstrate that a renal tubular developmental
morphogenetic protein-7 (BMP-7) prevents tubulointer-
stitial nephritis after experimental ureteral obstruction.
The underlying thrust of these fascinating experiments
is that we will have to rely on molecular biology both
to understand and treat at least some varieties of progres-
sive CKD.
During the early days of maintenance hemodialysis,
various comorbid extrarenal complications were viewed
as imposing absolute limits to the duration of life prolon-
gation. First, it was coronary artery disease, which is
now treated with diet modification and pharmacologic
regulation of lipids and hypertension. Next, the grim
entity of “renal osteodystrophy” gained center stage and
gradually became clarified as an admixture of extrarenal
calcification due to high Ca  P product plus bone de-
mineralization, resulting from hyperparathyroidism and
deficient vitamin D synthesis. With the advent of syn-
thetic vitamin D formulations and a menu of phosphate
binders, nephrologists face confusing choices in design-
ing a therapy for each patient.
Llach and Ferna´ndez provide a broad perspective on
how bone lesions in renal patients have evolved while
sketching their prediction of coming changes in therapy.
Emphasizing “an increase in the calcium burden and
hyperphosphatemia” as “major factors leading to the
high mortality of ESRD patients,” these investigators
analyze available drug choices. These investigators sug-
gest that the use of calcimimetic agents, a novel method
for stimulating the calcium-sensing receptor in the para-
thyroid gland, will lower parathormone secretion while
controlling secondary hyperparathyroidism. A clinical
trial of “Cinacalcet,” now in progress, has “resulted in
a significant decrease of Ca  P product.” Long-term
trials are needed to assess the effect of Cinacalcet on
survival and life quality of ESRD patients.
Central to all present strategies for preventing bone
disease in both CKD and ESRD patients is precise, reli-
able measurement of parathyroid hormone (PTH). Good-
man provides clarification in the selection of either a
“first-generation” or “second-generation” immunomet-
ric assay of PTH. Assay reliability “depends largely on
the extent to which results have been validated by bone
histomorphometry.” Whether measuring “full-length
biologically active PTH (1-84) exclusively” (second-gen-
eration), or detecting both “PTH (1-84) and other rela-
tively large amino-terminally-truncated PTH-derived
fragments (first generation), the relationship between
bone histology and plasma PTH levels was equivalent.
Goodman advises that the PTH target of 150 to 250
pg/mL for first-generation PTH assays should corre-
spond to approximately 75 to 125 pg/mL in second-gen-
eration assays. Coburn writes a comprehensive paper
that shows growing evidence for contributions of ele-
vated levels of serum calcium and serum phosphorus as
factors contributing to vascular and cardiac calcifications
in ESRD patients. He raises questions about whether
the current practice of vitamin D usage in ESRD patients
might be a contributing factor to such vascular abnormal-
ities. It is recommended that potential adverse vascular
effects of vitamin D sterols related to the increments of
serum calcium and phosphorus be carefully monitored
and evaluated by practitioners.
Affirming the report by Llach and Ferna´ndez, Block
gives further details of the completed phase 2 clinical
trial of Cinacalcet, a second-generation calcimimetic
agent that exerts positive allosteric modulation of the
calcium receptor, thereby increasing its sensitivity to ex-
tracellular calcium. Summarizing the case for preventing
vascular calcification rather than treating after-the-fact,
Block notes that in a 23-week double-blind, placebo-
controlled, randomized trial, Cinacalcet induced a30%
reduction in mean PTH levels in 74% of subjects versus
11% of placebo-treated subjects (P 0.001). The phase 3
trial is eagerly awaited.
Overall, the pages that follow illustrate the breadth
and accomplishment of investigators whose common
bond is the extension of life, while maximizing quality,
after onset of any of the still tragic disorders that com-
prise the hapless term of ESRD. Finally, this work was
helped by an unrestricted educational grant from Amgen
to Long Island College Hospital. My thanks to Dr. Rob-
ert Brenner for helping me make this very large body
of new information available to nephrologists, cardiolo-
gists, and practitioners throughout the world.
Morrell Michael Avram
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